Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00464178 · OUTCOME

Median Number of Cycles to Tumor Progression (TTP)

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2022-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Cycles Prior to Tumor Progression
Interval / dispersion
Full Range
Time frame
18 months

What was measured

Study Schema: Bortezomib will be administered on Days 1. 4, 8, and 11. Response will be assessed subsequent to each 21-day cycle. Progression is defined using the Bladé criteria, defined progression as an increase of \>25% in paraprotein or urinary light chain excretion (or marrow plasma cell percentage in the marrow

Groups in this outcome

Bortezomib and Bevacizumab

Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib and Bevacizumab6

Reported measurements

Source class 1
Values in Cycles Prior to Tumor Progression · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Bortezomib and Bevacizumab1.5Not reported110Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        10
        value
        1.5
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Study Schema: Bortezomib will be administered on Days 1. 4, 8, and 11. Response will be assessed subsequent to each 21-day cycle. Progression is defined using the Bladé criteria, defined progression as an increase of \>25% in paraprotein or urinary light chain excretion (or marrow plasma cell percentage in the marrow
dispersion Type
Full Range
groups
  1. description
    Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
    id
    OG000
    title
    Bortezomib and Bevacizumab
param Type
MEDIAN
reporting Status
POSTED
time Frame
18 months
title
Median Number of Cycles to Tumor Progression (TTP)
type
PRIMARY
unit Of Measure
Cycles Prior to Tumor Progression

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice